AVI BioPharma Announces Late-Breaker Oral Presentation of Phase IIb DMD Study at 2012 AAN Annual Meeting in April
12 Marzo 2012 - 6:30AM
Marketwired
AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based
therapeutics, today announced that an abstract describing the
Company's Phase IIb study evaluating eteplirsen for the treatment
of Duchenne Muscular Dystrophy has been accepted as part of the
American Academy of Neurology (AAN) Emerging Science program
(formerly known as the Late-Breaking Science program). The brief
oral presentation will take place during AAN's 64th Annual Meeting
in New Orleans, LA at the Ernest N. Morial Convention Center from
April 21 to April 28, 2012. AAN describes Emerging Science
Abstracts as works of major scientific importance and representing
scientific advances that emerged after the original October 2011
abstract deadline that warrant expedited presentation and
publication. AVI's abstract does not contain study results, but a
description of the study design and type of findings to be
presented at the meeting.
"The results of this study represent an important milestone for
the development of treatments for Duchenne Muscular Dystrophy and
we are pleased that AAN agreed to include this first
placebo-controlled study evaluating exon skipping in DMD as one of
the 15 Emerging Science Abstracts for the conference this year,"
said Chris Garabedian, president and CEO of AVI BioPharma.
Jerry R. Mendell, M.D., of Nationwide Children's Hospital and
principal investigator of the Phase IIb study, will deliver the
presentation #004 at the Emerging Science Session on Wednesday,
April 25 at approximately 5:54pm CDT. The presentation is titled "A
Phase IIb Placebo-Controlled Study of the Exon-Skipping Drug
Eteplirsen in Subjects with Duchenne Muscular Dystrophy." Abstracts
will be featured in AAN's "data blitz" format, which consists of
fifteen 3-minute oral presentations, during the first 45 minutes of
the session from 5:45pm to 6:30pm CDT, followed by a more detailed
poster presentation format from 6:30pm to 7:00pm CDT.
Dr. Mendell's presentation will be posted on the AVI BioPharma
web site in the "Events & Presentations" section after the
session is completed.
About Eteplirsen
Eteplirsen is AVI's lead drug candidate that is systemically
delivered for the treatment of a substantial subgroup of patients
with DMD. Data from clinical studies of eteplirsen in DMD patients
have demonstrated a broadly favorable safety and tolerability
profile and restoration of dystrophin protein expression.
Eteplirsen uses AVI's novel phosphorodiamidate morpholino
oligomer (PMO)-based chemistry and proprietary exon-skipping
technology to skip exon 51 of the dystrophin gene. By skipping exon
51, eteplirsen may restore the gene's ability to make a shorter,
but still functional, form of dystrophin from mRNA. Promoting the
synthesis of a truncated dystrophin protein is intended to improve,
stabilize or significantly slow the disease process and prolong and
improve the quality of life for patients with DMD.
AVI is also developing other PMO-based exon-skipping drug
candidates intended to treat additional patients with DMD.
About AVI BioPharma
AVI BioPharma is focused on the discovery and development of
novel RNA-based therapeutics for rare and infectious diseases, as
well as other select disease targets. Applying pioneering
technologies developed and optimized by AVI, the Company is able to
target a broad range of diseases and disorders through distinct
RNA-based mechanisms of action. Unlike other RNA-based approaches,
AVI's technologies can be used to directly target both messenger
RNA (mRNA) and precursor messenger RNA (pre-mRNA) to either
down-regulate (inhibit) or up-regulate (promote) the expression of
targeted genes or proteins. By leveraging its highly differentiated
RNA-based technology platform, AVI has built a pipeline of
potentially transformative therapeutic agents, including
eteplirsen, which is in clinical development for the treatment of
Duchenne muscular dystrophy, and multiple drug candidates that are
in clinical development for the treatment of infectious disease.
For more information, please visit www.avibio.com.
Forward-Looking Statements and
Information
In order to provide AVI's investors with an understanding of its
current results and future prospects, this press release contains
statements that are forward-looking. Any statements contained in
this press release that are not statements of historical fact may
be deemed to be forward-looking statements. Words such as
"believes," "anticipates," "plans," "expects," "will," "intends,"
"potential," "possible" and similar expressions are intended to
identify forward-looking statements. These forward-looking
statements include statements about the development of AVI's
product candidates and the efficacy, potency and utility of AVI's
product candidates in the treatment of rare and infectious
diseases.
These forward-looking statements involve risks and
uncertainties, many of which are beyond AVI's control. Known risk
factors include, among others: clinical trials may not demonstrate
safety and efficacy of any of AVI's drug candidates and/or AVI's
antisense-based technology platform; and any of AVI's drug
candidates may fail in development, may not receive required
regulatory approvals, or be delayed to a point where they do not
become commercially viable.
Any of the foregoing risks could materially and adversely affect
AVI's business, results of operations and the trading price of
AVI's common stock. For a detailed description of risks and
uncertainties AVI faces, you are encouraged to review the official
corporate documents filed with the Securities and Exchange
Commission. AVI does not undertake any obligation to publicly
update its forward-looking statements based on events or
circumstances after the date hereof.
AVI Media and Investor Contact: Erin Cox 425.354.5140 Email
Contact AVI Media Contact: David Schull 212.845.4271 Email
Contact
Avi Biopharma (NASDAQ:AVII)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Avi Biopharma (NASDAQ:AVII)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024